3-5
2026
影响因子区间
—
平台估算
14%
2025
中国作者发文占比
3150 CHF
收费
期刊简介:Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
【译文】糖尿病、肥胖和代谢学主要是一本关于临床和实验药理学及治疗学的期刊,涵盖糖尿病、肥胖和代谢相互关联的领域。该期刊优先考虑高质量的原创研究,这些研究报道了新疗法或现有疗法(包括饮食、运动和生活方式(非药理)干预)对代谢和内分泌疾病任何方面的影响,无论是人类还是动物和细胞系统。‘代谢’可能涉及脂质、骨骼和药物代谢,或更广泛的内分泌功能障碍方面。临床前药理学、药代动力学研究、荟萃分析和那些涉及药物安全性和耐受性的研究也非常适合在该期刊上发表。原创研究可以以主要论文或研究信函的形式发表。

| 指标 | 当前值 | 近三年趋势 |
|---|---|---|
| JCR分区 | Q1 | 暂无 |
| 影响因子区间 | 3-5 | 暂无 |